source
- Argenx’s FB102 meets primary endpoint in phase 2 celiac trial, paving way for pivotal studyArgenx reported that its experimental antibody FB102 achieved a statistically significant improvement in villus height‑to‑crypt depth (Vh:Cd) compared with placebo in a phase 2 study of adults with…
- FDA unveils transparency roadmap with plans for public NDA/BLA disclosures and inspection report publishingThe FDA published a transparency roadmap that outlines its FY 2026 achievements and sets out priorities for FY 2027. One key priority is a proposal to require public disclosure of new drug applica…